,i #aagth ,,congress #b;d ,session ,h4 ,r4 #gjjh ,,in ,,the ,,house ,,of ,,representatives ,march #i1 #bjbb,mr4 ,guthrie introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to improve patient access to emerging medication therapies by clarifying the scope of permitted health care economic and scientific information communications between biopharmaceutical manufacturers and population health decision makers1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,pre-approval ,information ,exchange ,act of #bjbb4 #b4 ,facilitating exchange of information prior to approval ,section #ejb7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #ceb7;a77 is amended-- 7#a7 by redesignating subparagraph 7#b7 as subparagraph 7#c72 7#b7 by inserting after subparagraph 7#a7 the following3 7#b7 7,a7 ,health care economic information1 scientific information1 or product support information provided to a covered payor responsible for the selection of drugs or devices for coverage1 reimbursement1 or other population-based health care management1 shall not be considered false or misleading or any other form of misbranding under this section or a violation of section #eje1 #eaj7k71 #eac1 or #eae of this ,act or section #cea of the ,public ,health ,service ,act1 or otherwise prohibited pre-approval promotion of a drug or device1 if it-- 7i7 7,i7 in the case of health care economic information1 is based on competent and reliable scientific evidence2 or 7,,ii7 in the case of scientific information other than health care economic information1 is truthful and nonmisleading2 and 7ii7 relates to an investigational drug or device or investigational use of a drug or device that is approved1 cleared1 or licensed under section #eje1 #eaj7k71 #eac1 or #eae of this ,act or section #cea of the ,public ,health ,service ,act 7as applicable74 7,b7 ,in order to provide information pursuant to this subparagraph relating to an investigational drug or device1 or an investigational use of an drug or device that has been approved1 granted marketing authorization1 cleared1 or licensed-- 7i7 the information must include-- 7,i7 a clear statement that the investigational drug or device or investigational use of a drug or device has not been approved1 cleared1 or licensed under section #eje1 #eaj7k71 #eac1 or #eae of this ,act or section #cea of the ,public ,health ,service ,act 7as applicable7 and that the safety and effectiveness of the drug or device or use has not yet been established2 7,,ii7 information related to the stage of development of the drug or device involved1 such as-- 7aa7 the status of any study or studies in which the investigational drug or device or investigational use is being investigated2 7bb7 how the study or studies relate to the overall plan for the development of the drug or device2 7cc7 whether a marketing application or notification for the investigational drug or device or investigational use has been submitted to the ,secretary and when such a submission is planned2 7,,iii7 in the case of communications that include factual presentations of results from studies1 a description of-- 7aa7 material aspects of study design1 methodology1 and results2 and 7bb7 material limitations related to the study design1 methodology1 and results2 and 7,,iv7 where applicable1 a conspicuous and prominent statement describing any material differences between the information provided and the labeling approved1 granted marketing authorization1 cleared1 or licensed pursuant to section #eje1 #eaj7k71 #eac1 or #eae of this ,act or section #cea of the ,public ,health ,service ,act4 7,c7 ,for purposes of this subparagraph-- 7i7 the term covered payor means a payor1 formulary committee1 drug information center1 technology assessment committee1 pharmacy benefit manager1 and other multidisciplinary entity that1 on behalf of health care organizations1 reviews scientific or technology assessments1 or other similar entity with knowledge and expertise to evaluate health care economic analysis or scientific information on a population basis2 7ii7 the term product support information includes-- 7,i7 information describing the drug or device 7such as drug class1 device description1 and features72 7,,ii7 information about the indication or indications sought2 7,,iii7 the anticipated timeline for a possible approval1 clearance1 or licensure pursuant to section #eje1 #eaj7k71 #eac1 or #eae of this ,act or section #cea of the ,public ,health ,service ,act2 7,,iv7 drug or device pricing information2 7,v7 patient utilization projections2 and 7,,vi7 product-related programs or services4 7iii7 the term scientific information includes clinical and pre-clinical data and results relating to a drug or device or use that has not been approved1 granted marketing authorization1 cleared1 or licensed and is being investigated or developed4 2 7#c7 in subparagraph 7#c71 as redesignated-- 7,a7 by striking 7,a72 7,b7 by striking clause 7,b72 and 7,c7 by striking drug each place it appears and inserting drug or device2 and 7#d7 by adding at the end the following3 7#d7 ,nothing in this section shall be construed to limit the ability of manufacturers or sponsors of drugs or devices to engage in communications or activities not specified in subparagraph 7#b7 or 7#c7 that are otherwise permissible4 4 #c4 ,,gao study and report ,beginning on the date that is #e years and #f months after the date of enactment of this ,act1 the ,comptroller ,general of the ,united ,states 7in this subsection referred to as the ,comptroller ,general7 shall conduct a study on the provision and use of information pursuant to section #ejb7;a77#b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by section #b of this ,act1 between manufacturers of1 and covered entities 7as defined in such section #ejb7;a77#b77 for1 drugs and devices 7as defined in section #bja of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba774 ,such study shall include an analysis of the following3 7#a7 ,the type of information communicated between such manufacturers and payors4 7#b7 ,the manner of communication between such manufacturers and payors4 7#c7 7,a7 ,whether such manufacturers file a submission for approval1 marketing authorization1 clearance1 or licensing of a new drug or device or the new use of a drug or device that is the subject of communication between such manufacturers and payors before the new use is approved1 granted marketing authorization1 cleared1 or licensed4 7,b7 ,how frequently the ,food and ,drug ,administration approves1 grants marketing authorization1 clears1 or licenses the new drug or device or new use4 7,c7 ,the timeframe between the initial communications under section #ejb7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as amended by this ,act1 regarding an investigational drug or device or investigational use1 and the initial marketing of such drug or device or investigational use4